CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort
Authors
Hall, M.Allan, K.
Michael, A.
Clamp, Andrew R
Glasspool, R.
Nicum, S.
Lord, R.
Banerjee, S. N.
Roche, J.
Stobo, J.
Gourley, C.
Affiliation
Mount Vernon Cancer Centre, Northwood, United KingdomIssue Date
2022
Metadata
Show full item recordCitation
Hall M, Allan K, Michael A, Clamp AR, Glasspool R, Nicum S, et al. CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301633.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5577Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5577Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5577